PubRank

F De Keyser

Author PubWeight™ 92.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001 2.96
2 Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2004 2.18
3 Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004 2.15
4 Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000 1.79
5 Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002 1.76
6 Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001 1.70
7 Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000 1.47
8 Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection. Acta Clin Belg 2014 1.43
9 Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol 1997 1.42
10 Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000 1.42
11 Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000 1.39
12 Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000 1.37
13 Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol 1999 1.36
14 Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010 1.34
15 Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004 1.32
16 Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005 1.31
17 Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003 1.31
18 A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) 2002 1.27
19 Rheumatoid nodules: differential diagnosis and immunohistological findings. Ann Rheum Dis 1993 1.23
20 Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2008 1.19
21 The antiperinuclear factor. Clin Exp Rheumatol 1991 1.18
22 Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990 1.16
23 The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 2001 1.15
24 Linkage of a polymorphic marker for the type III collagen gene (COL3A1) to atypical autosomal dominant Ehlers-Danlos syndrome type IV in a large Belgian pedigree. Hum Genet 1988 1.13
25 Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001 1.13
26 Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis 2002 1.11
27 Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev 2005 1.10
28 CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis 2004 1.06
29 Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2004 1.06
30 Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 2001 1.05
31 The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005 1.05
32 Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol 1999 1.02
33 Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 1993 1.01
34 Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) 2008 1.00
35 Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004 0.98
36 Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 2005 0.97
37 Chemical agents and enzymes used for the extraction of gut lymphocytes influence flow cytometric detection of T cell surface markers. J Immunol Methods 2000 0.97
38 Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010 0.96
39 Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis 2005 0.96
40 Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 2002 0.96
41 Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003 0.95
42 Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2004 0.95
43 Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 2001 0.94
44 Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis 2008 0.93
45 The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol 2001 0.93
46 Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Ann Rheum Dis 2004 0.93
47 Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis 2007 0.92
48 Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis. Ann Rheum Dis 2008 0.92
49 Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondyloarthropathy. Ann Rheum Dis 2004 0.92
50 Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. Am J Clin Pathol 2000 0.92
51 Polymorphisms in the ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis. Rheumatology (Oxford) 2007 0.91
52 Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998 0.91
53 Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1998 0.90
54 Churg-Strauss syndrome presenting as polymyositis. Clin Exp Rheumatol 1995 0.89
55 Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J Pathol 2002 0.88
56 Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis 2000 0.88
57 Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2005 0.88
58 Prediction of diagnosis in patients with early arthritis using a combined Kohonen mapping and instance-based evaluation criterion. Artif Intell Med 2004 0.87
59 Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis. Ann Rheum Dis 2006 0.87
60 Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastroenterol Belg 1998 0.86
61 The history of injectable biomaterials and the biology of collagen. Aesthetic Plast Surg 1985 0.85
62 Sensitivity of the HEp-2000 substrate for the detection of anti-SSA/Ro60 antibodies. Clin Rheumatol 2000 0.85
63 A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers. Ann Rheum Dis 1998 0.85
64 Functional haplotypes of PADI4: relevance for rheumatoid arthritis specific synovial intracellular citrullinated proteins and anticitrullinated protein antibodies. Ann Rheum Dis 2005 0.84
65 Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clin Exp Rheumatol 2002 0.84
66 Endogenous HLA-DR-restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint. Arthritis Rheum 2007 0.83
67 CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clin Exp Immunol 2005 0.82
68 Case number 34: Relapse of polyarteritis nodosa presenting as isolated and localised lower limb periostitis. Ann Rheum Dis 2005 0.82
69 Interlaboratory variability of the antiperinuclear factor (APF) test for rheumatoid arthritis. Clin Exp Rheumatol 1993 0.82
70 History and diagnostic value of antibodies to citrullinated proteins in rheumatoid arthritis. Int J Immunopathol Pharmacol 2004 0.82
71 Influence of the gut and cytokine patterns in spondyloarthropathy. Clin Exp Rheumatol 2002 0.81
72 Altered gut transcriptome in spondyloarthropathy. Ann Rheum Dis 2006 0.81
73 Broadening of the T cell receptor spectrum among rheumatoid arthritis synovial cell-lines in relation to disease duration. Clin Exp Rheumatol 2000 0.81
74 Over-representation of construction-related occupations in male patients with systemic sclerosis. Ann Rheum Dis 2008 0.81
75 Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo. Ann Rheum Dis 2007 0.81
76 A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis 2006 0.81
77 Case Number 29: Ochronosis: synovial histopathological characteristics. Ann Rheum Dis 2004 0.79
78 Changes in antinuclear serology in patients with spondylarthropathy under sulphasalazine treatment. Br J Rheumatol 1993 0.79
79 Review article: bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol Ther 1998 0.78
80 Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis 2001 0.78
81 Klinefelter's syndrome and scleroderma. J Rheumatol 1989 0.77
82 Work participation in patients with systemic sclerosis: a systematic review. Clin Exp Rheumatol 2014 0.77
83 Leflunomide and methotrexate combination therapy in daily clinical practice. Ann Rheum Dis 2006 0.77
84 Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 2012 0.77
85 Ehlers-Danlos syndrome type I: a clinical and ultrastructural study of a family with reduced amounts of collagen type III. Br J Dermatol 1987 0.77
86 The pathophysiology of lupus erythematosus. Eur J Dermatol 1999 0.76
87 Polyarteritis nodosa and the antiphospholipid syndrome. Clin Rheumatol 1996 0.76
88 An optimized method for routine HLA-B27 screening using flow cytometry. Cytometry 1994 0.76
89 Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis 2002 0.75
90 Proinflammatory cytokine production and cell adhesion molecule expression compared in rheumatoid nodules and synovial membranes: comment on the article by Wikaningrum et al. Arthritis Rheum 1999 0.75
91 Tenosynovitis with acute onset: unexpected giant cell tumour of the tendon sheath. Ann Rheum Dis 2002 0.75
92 Microscopic polyangiitis involving the breast. Acta Clin Belg 2011 0.75
93 Polyarteritis nodosa mimicking polymyalgia rheumatica. Clin Rheumatol 1999 0.75
94 The immunological basis of inflammatory bowel disease. Acta Gastroenterol Belg 1997 0.75
95 Classification models for disease: the effect of associations between markers on calculating the risk for disease by likelihood ratio products. Clin Exp Rheumatol 2009 0.75
96 Roentgenographic manifestation of pulmonary tuberculosis. Chest 1988 0.75
97 Validation of a new screening strategy for anti-extractable nuclear antigen antibodies. Clin Exp Rheumatol 2010 0.75
98 Unusual familial manifestation of Ehlers-Danlos syndrome. Prog Clin Biol Res 1982 0.75
99 Re: Pulmonary arterial hypertension in connective tissue diseases. Rheumatology (Oxford) 2007 0.75
100 A red face in a lupus patient: thinking beyond lupus rash. Acta Clin Belg 2010 0.75
101 Second conference on spondylarthropathies and the gut. Clin Exp Rheumatol 1994 0.75
102 Management of early inflammatory arthritis. Intervention with immunomodulatory agents: new pharmacological developments. Baillieres Clin Rheumatol 1992 0.75